Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.
High-Risk Myeloma Treatment Is Not One-Size-Fits-All
“Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high-risk myeloma.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Allogeneic CAR T-Cell Therapy Is Safe, Effective in Heavily Pretreated Myeloma
P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Cilta-Cel Is Safe, Efficacious in Real-World Treatment of Myeloma
Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.
Belantamab Mafodotin, KRd Is Promising in Relapsed/Refractory Myeloma
Belantamab mafodotin plus KRd had a a manageable safety profile and deep responses in pretreated multiple myeloma.
NT-I7 Enhances CAR T-Cell Efficacy in DLBCL
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd
Non-Operative Management of Rectal Cancer Does Not Worsen Distant RFS
Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer